Aclidinium bromide/formoterol fumarate vs Tiotropium bromide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

Aclidinium bromide/formoterol fumarate · Duaklir Pressair

Rights held by Azurity Pharmaceuticals and partners; US product discontinued

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Partial signal

NCT01437397 · Phase 3 · completed

This was a large randomized, quadruple-blind, placebo- and active-controlled trial with 1,692 randomized participants, using the regulator-accepted clinical lung-function measure FEV1 as its primary endpoint. Results were mixed: the 400/12 μg combination significantly improved post-dose FEV1 versus aclidinium and trough FEV1 versus formoterol, whereas the 400/6 μg combination did not significantly improve trough FEV1 versus formoterol (p=0.133).

Reported efficacy

Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate (Week 24, morning pre-dose (trough)); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) (met)

Result source: NCT03022097

Tiotropium bromide

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT02172287 · Phase 3 · completed

This 6-month trial randomly assigned 623 patients with COPD to tiotropium, salmeterol or placebo, with double-blind, double-dummy treatment. The two primary measures were trough FEV1 and the Transition Dyspnea Index (TDI). Tiotropium raised trough FEV1 by 0.14 L more than placebo, more than salmeterol did (0.09 L; p<0.01 for tiotropium against salmeterol), and improved the TDI focal score by 1.02 units against placebo (p=0.01). Both primary measures favoured tiotropium, so the result is met. The figures come from the peer-reviewed paper in Chest (2002).

Reported efficacy

Change from baseline in trough Forced expiratory volume in one second (FEV1) response (baseline, up to day 169); Change from baseline in Mahler Transitional Dyspnoea Index (TDI) (baseline, up to day 169): Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. (met)

Result source: NCT02172287

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAclidinium bromide/​formoterol fumarateTiotropium bromide
Moderate or severe exacerbations, annualised rate—Not reported0.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986
Trough FEV1, change0.1 vs -0.0+0.1 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788
SGRQ total, change-6.6 vs -2.2−4.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
4 other results
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470
TDI focal score2.0 vs 0.6+1.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
  • 2.9 vs 2.1 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • 1.9 vs 1.9 wk 24 · n 353 · Phase 3 · secondary NCT01908140
—Not posted · NCT02172287

Moderate or severe exacerbations, annualised rate

Aclidinium bromide/​formoterol fumarate
—Not reported
Tiotropium bromide
0.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986

Trough FEV1, change

Aclidinium bromide/​formoterol fumarate
0.1 vs -0.0+0.1 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
Tiotropium bromide
0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788

SGRQ total, change

Aclidinium bromide/​formoterol fumarate
-6.6 vs -2.2−4.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
4 other results
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
Tiotropium bromide
-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470

TDI focal score

Aclidinium bromide/​formoterol fumarate
2.0 vs 0.6+1.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
  • 2.9 vs 2.1 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • 1.9 vs 1.9 wk 24 · n 353 · Phase 3 · secondary NCT01908140
Tiotropium bromide
—Not posted · NCT02172287
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Aclidinium bromide/formoterol fumarate: 6 of 6 rows · Tiotropium bromide: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAclidinium bromide/​formoterol fumarate
Rows use multiple source trials
Tiotropium bromide
Rows use multiple source trials
FEV1 Change 1h
absolute change · L
0.247 vs -0.037 placebo L @ 24wk400/12 μga,b,c
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 1 more dose
0.226 vs -0.037 placebo L @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.253 vs 0.169 AB L @ 24wk400/12 μgb,c
NCT02796677 · Phase 3 · registry result, not featured evidence
FEV1 Peak
absolute change · L
0.324 vs 0.008 placebo L @ 24wk400/12 μgd,b,c
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
1 other source trial
1.655 vs 1.562 Salmeterol / Fluticasone L @ 24wk
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.26 vs 0.02 placebo L @ 24wkd,b,c
NCT00523991 · Phase 4 · registry result, not featured evidence
3 other source trials
0.216 vs 0.051 placebo L @ 24wk100 mcg
NCT00528996 · Phase 2 · registry result, not featured evidence
0.216 vs 0.051 placebo L @ 24wk200 mcg
NCT00528996 · Phase 2 · registry result, not featured evidence
0.207 vs 0.051 placebo L @ 24wk50 mcg
NCT00528996 · Phase 2 · registry result, not featured evidence
Dropout rate
19.5%400/12 μge
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
18.3%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.9%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
14.1%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
8.8%400/12 μg
NCT01462942 · Phase 3
10.5%400/6 μg
NCT01462942 · Phase 3
32.4%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
10.3%50/250 µg BIDf
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
15%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
33.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT00523991 · Phase 4 · registry result, not featured evidence
7.9%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
13.3%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
0%18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
23.2%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23.4%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
13.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
16.1%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
6.3%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
6.2%400/12 μge
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
6.5%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.1%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
4.7%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
3.1%400/12 μg
NCT01462942 · Phase 3
2.6%400/6 μg
NCT01462942 · Phase 3
6.6%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
6.4%50/250 µg BIDf
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
10.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT00523991 · Phase 4 · registry result, not featured evidence
2.4%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
10.6%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
11.1%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
10.5%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
3.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.2%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.1%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
1.1%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
5.7%400/12 μge
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
5.4%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.2%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
7.5%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
6%400/12 μg
NCT01462942 · Phase 3
4.7%400/6 μg
NCT01462942 · Phase 3
9.7%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
—50/250 µg BIDf
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
5.9%50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
8.8%50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.7%18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
37.5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
25.6%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
0%50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
3.8%50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
4.2%
NCT00523991 · Phase 4 · registry result, not featured evidence
3%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
0%
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
7.3%400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
32.9%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.9%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.8%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
0%150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
0%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
2%5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
3.7%5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
1.8%10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
0%tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
2.7%tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.4%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
400/12 μge
chronic obstructive pulmonary disease 15.2% (placebo 17.5%)
cough 5.1% (placebo 3.6%)
nasopharyngitis 4.8% (placebo 3.6%)
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
400/6 μg
chronic obstructive pulmonary disease 14.7% (placebo 17.5%)
nasopharyngitis 5.1% (placebo 3.6%)
cough 3.9% (placebo 3.6%)
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
upper respiratory tract infection 11.8% (placebo 8.9%)
chronic obstructive pulmonary disease 9.5% (placebo 13%)
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
chronic obstructive pulmonary disease 15%
headache 6%
nasopharyngitis 5.6%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
chronic obstructive pulmonary disease 8.6% (placebo 11.9%)
nasopharyngitis 7.8% (placebo 7.2%)
headache 7.5% (placebo 8.2%)
NCT01462942 · Phase 3
400/6 μg
chronic obstructive pulmonary disease 9.4% (placebo 11.9%)
nasopharyngitis 7.9% (placebo 7.2%)
headache 7.1% (placebo 8.2%)
NCT01462942 · Phase 3
400 μg/12 μg
chronic obstructive pulmonary disease 27%
urinary tract infection 6.6%
nasopharyngitis 6.4%
NCT01437540 · Phase 3 · registry result, not featured evidence
400/12 BID
protein urine present 15%
NCT03276078 · Phase 2 · registry result, not featured evidence
50/250 µg BIDf
nasopharyngitis 18.4%
dysphonia 13.2%
bronchitis 5.1%
NCT01762800 · Phase 4 · registry result, not featured evidence
show 27 more results
50/250 µg BID + 18 µg QD
nasopharyngitis 20.6%
bronchitis 10.3%
dysphonia 8.8%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18 µg QD + 50/250 µg BID
nasopharyngitis 26.7%
dysphonia 8%
bronchitis 6.7%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18μg
chronic obstructive pulmonary disease 37.5% (placebo 43.6%)
bronchitis 7.5% (placebo 5.1%)
insomnia 5% (placebo 5.1%)
NCT01663987 · Phase 4 · registry result, not featured evidence
18 μg
chronic obstructive pulmonary disease 25.6% (placebo 15.4%)
contusion 7.7% (placebo 0%)
oedema peripheral 7.7% (placebo 0%)
NCT01662986 · Phase 4 · registry result, not featured evidence
50/250 µg BID
dysphonia 5.9%
constipation 2%
dry mouth 2%
NCT01751113 · Phase 4 · registry result, not featured evidence
50/250 µg BID + 18 µg QD
dysphonia 9.6%
nasopharyngitis 5.8%
arthralgia 3.8%
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
nasophayngitis 6.7% (placebo 5%)
chronic obstructive pulmonary disease 4.6% (placebo 9.6%)
NCT00523991 · Phase 4 · registry result, not featured evidence
chronic obstructive pulmonary disease 6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary 15.6%
nasopharyngitis 11.5%
headache 5.1%
NCT02796677 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 32.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
18 mcg
chronic obstructive pulmonary disease 33.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
2.5 mcg
chronic obstructive pulmonary disease 33.8%
NCT01126437 · Phase 3 · registry result, not featured evidence
10 μg
cough 3.3% (placebo 0%)
headache 3.3% (placebo 3%)
urinary tract infection 3.3% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
40 μg
dry mouth 12.9% (placebo 0%)
dizziness 3.2% (placebo 6.1%)
back pain 0% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
20 μg
back pain 6.3% (placebo 3%)
headache 6.3% (placebo 3%)
cough 3.1% (placebo 0%)
NCT03118765 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 9.3% (placebo 4.1%)
dyspnoea 2% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
18 mcg
nasopharyngitis 4.8% (placebo 4.1%)
dyspnoea 2.1% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
2.5 mcg
dyspnoea 1.4% (placebo 9.5%)
nasopharyngitis 1.4% (placebo 4.1%)
NCT01222533 · Phase 2 · registry result, not featured evidence
1.25 mcg
nasopharyngitis 6.1% (placebo 4.1%)
dyspnoea 3.4% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 10.2%
chronic obstructive pulmonary disease 5.6%
NCT01040403 · Phase 2 · registry result, not featured evidence
10 mcg
nasopharyngitis 6.4%
chronic obstructive pulmonary disease 5.5%
NCT01040403 · Phase 2 · registry result, not featured evidence
tiotropium 5 mcg + olodaterol 10 mcg
chronic obstructive pulmonary disease 3.6%
nasopharyngitis 1.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 5 mcg + olodaterol 5 mcg
chronic obstructive pulmonary disease 7.3%
nasopharyngitis 2.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 10 mcg
nasopharyngitis 3.6%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 5 mcg
nasopharyngitis 7.1%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 10 mcg
nasopharyngitis 7.3%
chronic obstructive pulmonary disease 6.4%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 5 mcg
nasopharyngitis 11%
chronic obstructive pulmonary disease 3.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dTrial phases differ: Phase 4 versus Phase 3.
  5. ePopulation comparability has not been reviewed for 4 of these studies.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aclidinium bromide/formoterol fumarate

TDI Focal 2.017 vs 0.582 placebo score @ 24wk400/12 μg
absolute change · score
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
1.977 vs 0.582 placebo score @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
2.508 vs 1.215 placebo score @ 24wk400/12 μg
NCT01462942 · Phase 3
2.377 vs 1.215 placebo score @ 24wk400/6 μg
NCT01462942 · Phase 3
2.9 vs 2.1 placebo score @ 24wk400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
1.9 vs 1.9 Salmeterol / Fluticasone score @ 24wk
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3

Tiotropium bromide

Time to First Exacerbation 0.1 vs 0.33 TIO months50/250 µg BID
time to event · months
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 3 days as posted
show 5 more results
0.16 vs 0.33 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 5 days as posted
0 vs 0 TIO months*50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 0 days as posted
0 vs 0 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 0 days as posted
0.07 vs 0.33 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 2 days as posted
0.03 vs 0 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 1 days as posted
EXACT Total 27.83 vs 28.88 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.92 vs 28.88 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
38.26 vs 28.88 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.35 vs 28.8 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
37.58 vs 28.8 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.87 vs 28.8 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.63 vs 28.4 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.16 vs 28.4 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.57 vs 28.4 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.33 vs 28.93 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
35.92 vs 28.93 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.79 vs 28.93 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.98 vs 28.66 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
34.92 vs 28.66 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
34.03 vs 28.66 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.5 vs 28.8 TIO score @ 24wk50/250 µg BID
absolute value · score
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
32.72 vs 28.8 TIO score @ 24wk50/250 µg BID + 18 µg QD
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.67 vs 28.8 TIO score @ 24wk18 µg QD + 50/250 µg BID
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.76 vs 7.18 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
12.39 vs 7.18 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
13.23 vs 7.18 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.75 vs 6.99 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.86 vs 6.99 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.11 vs 6.99 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.69 vs 6.7 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.79 vs 6.7 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.3 vs 6.7 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.23 vs 6.82 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.66 vs 6.82 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.26 vs 6.82 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.33 vs 6.85 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
10.8 vs 6.85 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
9.89 vs 6.85 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination

+ 112 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide/formoterol fumarate's landscape · Tiotropium bromide's landscape